8-K: Orgenesis Increases Authorized Shares to 150 Million

Orgenesis Inc. stockholders approved an amendment to increase authorized common stock from 14.58 million to 150 million shares.

Summary

• Stockholders approved an amendment to the Articles of Incorporation to increase authorized common stock from 14,583,333 to 150,000,000 shares.
• The company held a special meeting on May 27, 2026, where 65.27% of outstanding shares were represented.
• Shareholders ratified the appointment of Kesselman & Kesselman C.P.A.s as the independent auditor for the 2025 fiscal year.
• The company confirmed the approval of a Convertible Loan Agreement dated September 10, 2025, involving Theracell Laboratories IKE and Alpha Prosperity Fund SPC.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development for existing shareholders due to the extreme dilution potential and the company's current status on the OTC Expert Market.

Positives

• Strong shareholder support for the share increase proposal with 5,153,345 votes in favor.
• Successful ratification of the independent registered public accounting firm.
• Clear path forward for the previously agreed-upon Convertible Loan Agreement.

Negatives

• Significant dilution risk for existing shareholders due to the massive increase in authorized shares.
• The company is currently trading on the OTC Expert Market, indicating a loss of major exchange listing status.
• The stock has been downgraded through multiple OTC tiers since October 2024.

Risks

• Potential for substantial equity dilution following the authorization of 150 million shares.
• Continued trading on the OTC Expert Market limits liquidity and institutional investor participation.
• Reliance on convertible debt financing to sustain operations.

Future Outlook

The company intends to utilize the increased authorized share count to facilitate the issuance of shares under the previously established Convertible Loan Agreement.

Management Comments

• Vered Caplan, CEO, signed the report confirming the corporate actions taken at the special meeting.

Industry Context

StockSavvy.ai notes that Orgenesis's transition to the OTC Expert Market and the massive expansion of authorized shares are typical of distressed biotech firms attempting to secure liquidity through dilutive financing arrangements.

Comparison to Industry Standards

• The company's delisting from Nasdaq to the OTC Expert Market places it outside the standard liquidity profiles of major biotech peers.
• The authorization of a 10x increase in shares is aggressive compared to standard capital structure adjustments in the sector.

Corporate Governance

Stakeholder Impact

• Existing shareholders face significant dilution.
• Creditors involved in the Convertible Loan Agreement gain increased flexibility for debt conversion.

Next Steps

• Issuance of shares related to the Convertible Loan Agreement.
• Continued operations under the OTC Expert Market listing.

Key Dates

Recommendation

The combination of delisting from a major exchange and a massive increase in authorized shares suggests significant financial distress and high dilution risk, making the stock unattractive for most investors.

Keywords

Orgenesis, authorized shares, convertible loan, OTC Expert Market, shareholder meeting, biotech